Virus Diseases

377 trials 110 recruiting

Filter these 377 trials by phase, country and sponsor.

Open in Search →

A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with po… Ended

2024-517199-39-00 COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYND 4 2025-03-19
EMAPALUMAB TREATMENT FOR ANTICIPATED CLINICAL BENEFIT IN SEPSIS DRIVEN BY THE INTERFERON-GAMMA ENDOTYPE (THE EMBRACE TRIAL) Ended

2024-515255-38-00 SEPSIS 4 2025-03-12
Long Acting Cabotegravir plus Rilpivirine in People Living with HIV-1 (PLHIV) Aged ≥ 60 Years for 96 weeks. Ended

2022-502882-53-00 HIV-1 6 2025-03-03
A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Partic… Ended

2023-509588-25-00 Hepatitis B 4 2025-02-11
Phase II proof-of-concept, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of plitidepsin in adults w… Ended

2024-516378-31-00 post-COVID-19 Condition (PCC) 4 2025-02-07
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND-… Ended

2024-514047-28-00 HIV-1 Infection 5 2025-01-27
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppres… Ended

2024-514046-37-00 HIV-1 Infection 5 2025-01-16
Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Ended

2024-511016-25-00 Chronic hepatitis B infection 4 2025-01-15
Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study) Ended

2023-504952-87-00 Human Immunodeficiency Virus 6 2025-01-13
ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO… Ended

2023-504594-20-00 Healthy volunteers 1 2025-01-06
VAXXAIR TRIAL: In-depth Immunological Analysis of Airway Immunity following Nasal Live Attenuated and Intramuscular Influenza Vaccine A ran… Ended

2023-506166-31-01 Influenza 6 2024-12-23
PH 3b, CAB + RPV in people with suboptimal response to oral ART (CROWN) Ended

2024-515070-28-00 HIV Infections 5 2024-12-23
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) Ended

2023-507891-31-00 Human Immunodeficiency Virus (HIV-1) infection 10 2024-10-11
Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care Ended

2022-501707-27-01 COVID-like-illness 10 2024-10-03
A study to investigate the safety and efficacy of fostemsavir in heavily treatment experienced people living with HIV-1 resistant to other d… Ended

2024-513930-39-00 Heavily Treatment Experienced Subjects Infected with Mu 5 2024-08-30
A phase 2a, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of RBD1016 in participants with chronic hepatitis D viru… Ended

2023-509007-33-00 Chronic hepatitis D virus infection 4 2024-08-21
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
Vaccination to prevent Mpox Infection (MPOX-VAX Study) Ended

2023-507881-19-00 Mpox infection 6 2024-06-29
Safety and Impact of Dasatinib on Inflammation and AIDS virus in People under treatment Ended

2024-513714-36-01 Human immunodeficiency virus 4 2024-06-28
Effect of nucleoside reverse transcriptase inhibitors on innate immune priming Ended

2023-510378-14-00 modulation of the innate immune system in healthy subje 3 2024-06-20
Treat-CMV Ended

2022-500714-25-01 congenital CMV infection 5 2024-06-19
Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options (FOST Switc… Ended

2023-504192-25-00 HIV-1 6 2024-06-05
A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi… Ended

2022-502099-22-01 HIV-1 Infection 5 2024-04-29
IAVI C110 HIV Vaccine Trial Ended

2023-508157-15-01 Human Immunodeficiency Virus (HIV) 1 2024-03-19